{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:47:08Z","timestamp":1781880428539,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to comprehensively characterize the clinical and pathological features, treatment strategies, and outcomes of patients with neural epidermal growth factor-like 1 protein (NELL-1)-positive membranous nephropathy (MN).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed non-systemic lupus erythematosus (SLE) MN patients diagnosed between January 2010 and August 2021 at Cangzhou Central Hospital, China. Inclusion required negative PLA2R and THSD7A staining and available paraffin-embedded renal tissue. Clinical, laboratory, pathological, treatment, and outcome data were collected and analyzed descriptively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 531 non-SLE MN cases screened, 23 patients (13 males, 10 females; mean age 49.4\u202f\u00b1\u202f12.0\u202fyears) were identified as NELL-1(+), PLA2R(\u2212), and THSD7A(\u2212). Hypertension was present in 26.1%, and nephrotic syndrome in 60.9% of patients. Bright granular NELL-1 deposits along glomerular capillary loops were observed in all cases, with segmental or incomplete global distribution seen in 65.2%. IgG4 and IgG1 were the predominant immunoglobulin subclasses (82.6 and 78.2%, respectively). Over a median follow-up of 56\u202fmonths, 73.9% received immunosuppressive therapy, while 26.1% were managed with supportive treatment alone. The overall remission rate was 87.0% (73.9% complete, 13.0% partial), with only two patients experiencing transient renal function decline and none progressing to end-stage renal disease. Notably, 26.1% of patients developed malignancies, most commonly lung cancer. In patients with malignancy, tumor resection and supportive therapy alone frequently led to remission of MN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>NELL-1-positive MN is characterized by high rates of IgG1 and IgG4 deposition and generally favorable responses to therapy. A substantial proportion of patients were diagnosed with malignancy, highlighting the importance of cancer screening in this population. Timely identification and management of underlying malignancy may contribute to improved renal outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1615855","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:35:26Z","timestamp":1756964126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical and pathological characteristics of NELL-1-positive membranous nephropathy: a case series study"],"prefix":"10.3389","volume":"12","author":[{"given":"Kang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/cjn.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/s0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient\u2019s care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"845767","DOI":"10.3389\/fimmu.2022.845767","article-title":"Novel biomarkers in membranous nephropathy","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"859419","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/ndt\/gfab356","article-title":"The role of Pla2r antibody monitoring: what we know and what we do not know","volume":"38","author":"Ronco","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2215\/cjn.0000000000000237","article-title":"Anti-Pla2r antibody levels and clinical risk factors for treatment nonresponse in membranous nephropathy","volume":"18","author":"Barbour","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin Type-1 domain-containing 7a in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1172\/jci85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7a induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J Clin Invest"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (Nell-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ajpath.2021.11.006","article-title":"Nell-1 in genome-wide association studies across human diseases","volume":"192","author":"Cheng","year":"2022","journal-title":"Am J Pathol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1006\/geno.1996.0628","article-title":"Cloning and characterization of two novel human Cdnas (Nell1 and Nell2) encoding proteins with six Egf-like repeats","volume":"38","author":"Watanabe","year":"1996","journal-title":"Genomics"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12033-011-9440-4","article-title":"Efficient production and characterization of recombinant human Nell1 protein in human embryonic kidney 293-F cells","volume":"51","author":"Hasebe","year":"2012","journal-title":"Mol Biotechnol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/cjn.11860720","article-title":"Neural epidermal growth factor-like 1 protein-positive membranous nephropathy in Chinese patients","volume":"16","author":"Wang","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/15563650.2023.2188141","article-title":"Mercury-associated neural epidermal growth factor-like 1 protein (Nell-1) positive membranous nephropathy after use of skin lightening creams","volume":"61","author":"Sultan","year":"2023","journal-title":"Clin Toxicol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/nep.14403","article-title":"Nell-1 membranous nephropathy due to mercury exposure from fairness cream: report of two cases","volume":"29","author":"Jawandhiya","year":"2024","journal-title":"Nephrology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.kint.2020.06.014","article-title":"The clinicopathologic spectrum of segmental membranous glomerulopathy","volume":"99","author":"Kudose","year":"2021","journal-title":"Kidney Int"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","article-title":"Nell1 is a target antigen in malignancy-associated membranous nephropathy","volume":"99","author":"Caza","year":"2021","journal-title":"Kidney Int"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the Kdigo 2021 guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1172\/jci72270","article-title":"Membranous nephropathy: from models to man","volume":"124","author":"Beck","year":"2014","journal-title":"J Clin Invest"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/bio.2012.1022","article-title":"Storage, retrieval, and distribution of biological materials for research International Society for Biological and Environmental Repositories","volume":"10","year":"2012","journal-title":"Biopreserv Biobank"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1016\/j.jacc.2019.03.507","article-title":"ACC\/AHA versus ESC\/ESH on hypertension guidelines: JACC Guideline Comparison","volume":"73","author":"Bakris","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1046\/j.1523-1755.1999.00299.x","article-title":"The Banff 97 working classification of renal allograft pathology","volume":"55","author":"Racusen","year":"1999","journal-title":"Kidney Int"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/ki.2012.280","article-title":"The Kdigo practice guideline on glomerulonephritis: Reading between the (guide)lines--application to the individual patient","volume":"82","author":"Radhakrishnan","year":"2012","journal-title":"Kidney Int"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/clc.23665","article-title":"Kidney outcomes using a sustained \u226540% decline in Egfr: a Meta-analysis of Sglt2 inhibitor trials","volume":"44","author":"Cherney","year":"2021","journal-title":"Clin Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.2215\/cjn.04800511","article-title":"Differential diagnosis of lupus and primary membranous nephropathies by igg subclass analysis","volume":"7","author":"Song","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/modpathol.2012.237","article-title":"Igg subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression","volume":"26","author":"Huang","year":"2013","journal-title":"Mod Pathol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/ckj\/sfv049","article-title":"Glomerular igg subclasses in idiopathic and malignancy-associated membranous nephropathy","volume":"8","author":"L\u00f6nnbro-Widgren","year":"2015","journal-title":"Clin Kidney J"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e34713","DOI":"10.7759\/cureus.34713","article-title":"A rare case of neural epidermal growth factor-like 1 protein (Nell-1) antigen-associated membranous nephropathy","volume":"15","author":"Mohamed Jiffry","year":"2023","journal-title":"Cureus"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e49892","DOI":"10.7759\/cureus.49892","article-title":"A case of spontaneous remission of membranous nephropathy after the removal of nerve epidermal growth factor-like 1 positive sigmoid Colon carcinoma","volume":"15","author":"Fujii","year":"2023","journal-title":"Cureus"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1615855\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:35:26Z","timestamp":1756964126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1615855\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":31,"alternative-id":["10.3389\/fmed.2025.1615855"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1615855","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"article-number":"1615855"}}